Ò»¡¢Æ÷¹ÙоƬΪÒÒ¸ÎÒ©Î↑·¢´òÏ»ù´¡
ÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©Ñ¬È¾ÏÖÔÚÎÞ·¨ÖÎÓú£¬ËüÓ°Ïì×ÅÈ«Çò¼¸ÒÚÈË¡£ÓÉÓÚȱ·¦ÄÜÓÃÓÚ²âÊÔDZÔÚÁÆ·¨µÄÄ£×Ó£¬ÖÎÁÆÁìÓòÉú³¤»ºÂý¡£¿ËÈÕ£¬Â׶ص۹úÀí¹¤Ñ§Ôº£¨Imperial College London£©µÄ¿ÆÑ§¼ÒÃÇÔÚÈËÔìÆ÷¹ÙÄ£×ÓÖвâÊÔÁ˲¡¶¾Ñ¬È¾£¬ÕâÒ»ÀÖ³ÉÓÐÍû¼ÓËÙ¸ÃÁìÓòµÄÑо¿¡£Ïà¹ØÂÛÎÄÒѽÒÏþÔÚ¡¶Nature Communications¡·ÉÏ¡£
ÈËÔìÆ÷¹ÙÄÜÄ£ÄâÕû¸öÆ÷¹ÙµÄϸ°û×é³ÉºÍÐÄÀíÐÔÄÜ£¬ÔÚÒ©ÎïÇå¾²ÐÔ²âÊÔÖÐÄÜ×÷Ϊ¶¯ÎïÄ£×ÓµÄÌæ»»Æ·£¬µ«Æù½ñΪֹËüÃÇ»¹Ã»Óб»ÓÃÓÚ²âÊÔѬȾÐÔ¼²²¡ÓëÆ÷¹ÙµÄÏ໥×÷Óᣵ۹úÀí¹¤µÄÑо¿ÕßʹÓÃÁËÈËÔì¸ÎÔàµÄÆ÷¹ÙоƬ£¨Organs-on-chips£©£¬²âÊÔËü¶ÔÒÒÐ͸ÎÑײ¡¶¾Ñ¬È¾µÄ·´Ó¦£¬À´È·¶¨²¡ÔÌåÓëÈËÔìÆ÷¹ÙµÄÏ໥×÷Óá£
Æ÷¹ÙоƬ½«ÈËÌå»îϸ°û°²ÅÅÔÚÓëÄ¿µÄÆ÷¹ÙµÄÐÄÀí¡¢»úеºÍ½á¹¹¶¼ÏàËÆµÄ½ÅÊÖ¼ÜÉÏ¡£Ï¸°ûÖÜΧÓе¼¹ÜÄ£ÄâÁ÷¹ýÉíÌåµÄѪÁ÷£¬Ò©Îï»òÕß²¡¶¾¾Óɵ¼¹ÜÁ÷Ï꾡°û¡£Óë¹Å°åÒªÁìÏà±È£¬ÓÃÓÚ²âÊԵĻîϸ°ûÔÚоƬÉÏÒ»Á¬Ê±¼ä¸ü³¤£¬²¢ÇұȹŰåµÄÄ£×ÓϵͳÐèÒªµÄѬȾ¼ÁÁ¿¸üµÍ¡£Ð§¹ûÅú×¢£¬Æ÷¹ÙоƬÉϵĸÎÔàϸ°û¿ÉÒÔѬȾÐÄÀíˮƽµÄHBV£¬²¢ÇÒ¶Ô²¡¶¾±¬·¢ÓëÕæÈ˸ÎÔàÏàËÆµÄÉúÎïѧ·´Ó¦£¬°üÀ¨ÃâÒßϸ°û»î»¯ºÍÆäËûѬȾ±ê¼Ç¡£±ðµÄ£¬Õâ¸öƽ̨չÏÖÁËHBV²¡¶¾ÌÓ±ÜÄÚÔÚÃâÒß·´Ó¦µÄÖØ´óÊֶΣ¬ÕâÒ»·¢Ã÷»ò¿ÉÓÃÓÚδÀ´µÄÒ©Î↑·¢¡£Ö»¹ÜÕâÏîÊÖÒÕÉд¦ÓÚÔçÆÚ½×¶Î£¬µ«Ñо¿ÕßÌåÏÖ£¬ËüÖÕÓпÉÄÜÈû¼Õß»ñµÃÐÂÐ͸öÌ廯ҩÎï¡£ÔÚδÀ´Ò½ÉúÓÐÍûʹÓÃÀ´×ÔÏÖʵ»¼ÕßµÄϸ°û£¬¶ø²»ÊÇͨÓÃϸ°ûϵ£¬À´²âÊÔÆä¶ÔijЩҩÎïµÄ·´Ó¦£¬´Ó¶øÊ¹ÖÎÁƸü¾ßÕë¶ÔÐÔ¡£
ÂÛÎÄÖ÷Òª×÷ÕßMarcus Dorner²©Ê¿Ëµ£º¡°ÕâÊǵÚÒ»´ÎʹÓÃÆ÷¹ÙоƬÊÖÒÕÀ´²âÊÔ²¡¶¾Ñ¬È¾£¬ÎÒÃǵÄÊÂÇé´ú±íÁËÕâÏîÊÖÒÕµÄÏÂÒ»¸öÓ¦ÓÃÇ°ÑØ£¬ÎÒÃÇÏ£ÍûËüÖÕÄܹ»½µµÍÓëÁÙ´²ÊÔÑéÏà¹ØµÄ±¾Ç®ºÍʱ¼ä£¬´Ó¾ÃÔ¶À´¿´Õ⽫ÓÐÀûÓÚ»¼Õß¡£¡±
¶þ¡¢ÐÂÁÙ´²ÊÔÑéÁ¦Õù¸ÄÉÆ»¼Õ߸ÎÏËά»¯ºÍ¸ÎÓ²»¯
Intercept¹«Ë¾¿ËÈÕÐû²¼£¬Æä¼´½«¿ªÕ¹ÃûΪREVERSEµÄ3ÆÚÁÙ´²ÊÔÑéÑо¿¡£¸ÃÑо¿ÊÇÒ»ÏîËæ»ú¡¢Ë«Ã¤¡¢Î¿½å¼Á±ÈÕÕ¡¢¶àÖÐÐĵÄÑо¿£¬½«ÔÚÔ¼540Àý¾»î¼ìÈ·ÕïΪ·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎÑ×£¨NASH£©ÒýÆðµÄ¸ÎÓ²»¯µÄ»¼ÕßÖУ¬ÆÀ¹ÀʹÓðÂɳµ¨Ëᣨoceticholic acid£¬OCA£©µÄÁÆÐ§ºÍÇå¾²ÐÔ¡£
·Ç¾Æ¾«ÐÔÖ¬·¾ÐÔ¸ÎÑ×£¨NASH£©ÊÇÒ»ÖÖÖ¬·¾ÔÚ¸ÎÔàÖÐȺ¼¯µÄ¸Î²¡£¬¿ÉÄܻᵼÖ¸ÎÏËά»¯ºÍ¸ÎÓ²»¯¡£¾ÝÔ¤¼Æ£¬NASH½«ÔÚ²»¾Ãºó³ÉΪÍíÆÚ¸Î²¡µÄ³£¼ûÔµ¹ÊÔÓÉ£¬ÕâЩ»¼Õßͨ³£¶¼ÐèÒª¸ÎÒÆÖ²¡£ÏÖÔÚûÓлñÅúµÄÓÃÓÚNASHµÄÖÎÁƼƻ®£¬ÕâÒ»ÁìÓòÉÐÓÐÖØ´óµÄÒ½ÁÆÐèÇó´ýÖª×ã¡£
REVERSEÊÔÑ齫ÔÚ±±ÃÀ¡¢Å·ÖÞ¡¢°Ä´óÀûÑǺÍÐÂÎ÷À¼µÈµØ¾ÙÐС£Ö÷ÒªÖÕµãÊÇÔÚÖÎÁÆ12¸öÔºó£¬Ê¹ÓÃNASHÁÙ´²Ñо¿ÍøÂ磨CRN£©ÏµÍ³ÆÀ·Öʱ£¬ÖÁÉÙ·ºÆðÒ»¸ö½×¶ÎµÄ¸ÎÏËά»¯×é֯ѧ¸ÄÉÆµÄÊÜÊÔÕßËùÕ¼µÄ°Ù·Ö±È¡£»¼Õß½«ÒÔ1£º1£º1µÄ±ÈÀýËæ»ú·ÖÅÉÖÁÈý¸ö×飬»®·Ö½ÓÊÜÖðÈÕÒ»´ÎOCA 10mg£¬µ«ÔÚÈý¸öÔÂʱµÎ¶¨ÖÁ25mg»òÕßο½å¼Á¡£ÀÖ³ÉÍê³ÉREVERSE˫ä½×¶ÎµÄ»¼Õß½«ÓÐ×ʸñ¼ÓÈ볤´ï12¸öÔµĿª·Å±êÇ©À©Õ¹½×¶ÎÊÔÑé¡£
¡°NASHºÜ¿ì½«ÓâÔ½±ûÐ͸ÎÑ×£¬³ÉΪÃÀ¹úºÍÅ·ÖÞ¸ÎÒÆÖ²µÄÖ÷ÒªÔµ¹ÊÔÓÉ£¬Òò´Ë¼±ÐèÓÐÓõÄÖÎÁÆÒªÁìÀ´Äæ×ª»¼ÕߵĸÎÏËά»¯ºÍ¸ÎÓ²»¯£¬¡±Intercept×ܲüæÏ¯Ö´ÐйÙMark Pruzanski²©Ê¿ÆÀ¼Û˵£¬¡°OCAÊÇÏÖÔÚ»ñµÃÃÀ¹úFDAÍ»ÆÆÐÔÁÆ·¨È϶¨µÄNASHÒ©Îï£¬Ëæ×Å3ÆÚÁÙ´²Ñо¿REGENERATEºÍREVERSEµÄÏ£Íû£¬ÎÒÃÇÓÐÍû½«¸ö»ñÅúµÄÁÆ·¨´ø¸ø»¼ÓиÎÏËά»¯ºÍ¸ÎÓ²»¯µÄNASH»¼Õߣ¬ËûÃÇÓнϸߵÄΣº¦±¬·¢¸Î¹¦Ð§Ë¥½ß¡£¡±
²Î¿¼×ÊÁÏ£º
[1] Poxel Presents Preclinical Proof-of-Concept Data for PXL770 in Non-Alcoholic Steatohepatitis (NASH) at Global NASH Congress 2018
[2] ContraVir Pharmaceuticals Announces TXL? Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population
[3] Organ-on-chip technology enters next stage as experts test hepatitis B virus
[4] Intercept Announces Phase III REVERSE Trial Evaluating OCA for the Treatment of NASH Patients With Compensated Cirrhosis


Ãö¹«Íø°²±¸ 35092602000113ºÅ